Successfully tested in-vitro on IBD models on caco-2 cell lines, for treating inflammatory conditions of the tissue as well as strong anti-permeability effect. We are beginning our first clinical trial on Proctitis.

Following products will be treating esophagitis, colitis, gastritis and Crohn's.

New formulation tested in-vitro for various inflammatory conditions. Tested in two small scale clinical trials for UV exposure and for Atopic Dermatitis. Currently running a third small scale clinical trial testing skin barrier function and erythema.

New formulation tested in-vitro on corneal epithelial cell lines for a strong, synergistic anti inflammatory effect. Also tested on a rabbit model for dry eye treatment, extending Tear film Breakup Time, and conjunctival epithelium repair. Human clinical trial to be completed by end of Q3 2025.